Comment on “Guidelines of care for the management of basal cell carcinoma” - 15/10/18
Doi : 10.1016/j.jaad.2018.05.1261
Lieke C.J. van Delft, MD a, b, ⁎ 
, Maud H.E. Jansen, MD a, b, Klara Mosterd, MD, PhD a, b, Nicole W.J. Kelleners-Smeets, MD, PhD a, b
, Maud H.E. Jansen, MD a, b, Klara Mosterd, MD, PhD a, b, Nicole W.J. Kelleners-Smeets, MD, PhD a, b a Department of Dermatology, Maastricht University Medical Centre+, Maastricht, The Netherlands
b GROW-School for Oncology and Developmental Biology Maastricht University Medical Centre+, Maastricht, The Netherlands
∗Correspondence to: Lieke C. J. van Delft, Maastricht University Medical Centre+, PO Box 5800, 6229 HX Maastricht, The NetherlandsMaastricht University Medical Centre+PO Box 5800HX Maastricht6229The Netherlands
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosure: Dr Mosterd has received sachets of imiquimod from Meda Connects (now called Mylan Connects) for an unrelated trial (NCT02242929 on clinicaltrials.gov/). The other authors declared no conflicts of interest. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 79 - N° 5
P. e99-e100 - novembre 2018 Retour au numéro
Article précédent
- Use of sterile urine cups as sharps containers during Mohs micrographic surgery stages
- Jessica Olander, Misha Miller, Mariah Brown
- Reply to: “Comment on ‘Guidelines of care for the management of basal cell carcinoma’”
- Christopher K. Bichakjian, Murad Alam
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?